03.24.25 -- Are CDMO Partnerships The Answer To Manufacturing Capacity Issues?

Developing a robust, phase-appropriate potency strategy is essential for ensuring the quality, consistency, and regulatory success of cell and gene therapies.

Intensified adherent cell culture offers a promising solution to the limitations of traditional suspension culture, with the potential to improve efficiency, reduce costs, and accelerate development.

Industry experts answer attendees' questions from a recent webinar about sustainability concerns surrounding oligonucleotide manufacturing.

Explore more detail on how to achieve a 2000L scale-up and studies that have been optimized through process characterization and experimental approaches to better understand key process steps.

Revolutionize advanced therapy logistics by prioritizing patient impact at every step of the supply chain to ensure life-saving treatments are delivered with integrity and precision.

As the field grows, understanding how to formulate RNA nanoparticles effectively is essential for advancing therapeutic innovations.

Extracellular vesicles hold immense potential for treating diseases, owing to their natural biocompatibility and ability to carry a diverse arsenal of therapeutic molecules.

Growth in rAAV-based therapies is creating a need for dramatically increased production. Learn how AAV productivity can be optimized using platform technologies capable of affording significantly higher titers.